Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Oct 23, 2019

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer’s disease program targeting neurotoxic forms of tau

Oct 17, 2019

ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau

Oct 8, 2019

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy

Sep 16, 2019

ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit

Sep 3, 2019

ProMIS Neurosciences to Present at H.C. Wainwright Investor Conference

Sep 3, 2019

ProMIS Neurosciences to Present at HC Wainwright Investment Conference

Aug 27, 2019

ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer’s Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

Aug 27, 2019

ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board

Aug 13, 2019

ProMIS Neurosciences Announces Second Quarter 2019 Results

  • arrow_back
  • 1…
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • …27
  • arrow_forward
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.